CVS Health Corporation $CVS Shares Sold by Camelot Portfolios LLC

Camelot Portfolios LLC lessened its stake in CVS Health Corporation (NYSE:CVS) by 2.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 7,422 shares of the pharmacy operator’s stock after selling 176 shares during the period. Camelot Portfolios LLC’s holdings in CVS Health were worth $512,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. San Luis Wealth Advisors LLC acquired a new position in shares of CVS Health in the second quarter worth $674,000. Patton Albertson Miller Group LLC grew its stake in shares of CVS Health by 5.8% during the second quarter. Patton Albertson Miller Group LLC now owns 17,228 shares of the pharmacy operator’s stock worth $1,188,000 after purchasing an additional 940 shares in the last quarter. Guyasuta Investment Advisors Inc. grew its stake in shares of CVS Health by 39.3% during the second quarter. Guyasuta Investment Advisors Inc. now owns 4,713 shares of the pharmacy operator’s stock worth $325,000 after purchasing an additional 1,330 shares in the last quarter. Worth Financial Advisory Group LLC grew its stake in shares of CVS Health by 4.2% during the second quarter. Worth Financial Advisory Group LLC now owns 6,740 shares of the pharmacy operator’s stock worth $465,000 after purchasing an additional 272 shares in the last quarter. Finally, Uncommon Cents Investing LLC grew its stake in shares of CVS Health by 3.9% during the second quarter. Uncommon Cents Investing LLC now owns 37,345 shares of the pharmacy operator’s stock worth $2,576,000 after purchasing an additional 1,406 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insiders Place Their Bets

In related news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.22% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS opened at $75.80 on Friday. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $77.34. The firm has a market capitalization of $96.14 billion, a price-to-earnings ratio of 21.17, a PEG ratio of 0.84 and a beta of 0.62. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The firm’s fifty day simple moving average is $69.13 and its 200 day simple moving average is $66.99.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio is currently 74.30%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CVS shares. Barclays lifted their target price on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Jefferies Financial Group increased their target price on shares of CVS Health from $74.00 to $80.00 and gave the company a “buy” rating in a report on Monday, June 30th. Zacks Research downgraded CVS Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Sunday, September 21st. Finally, UBS Group upgraded shares of CVS Health from a “neutral” rating to a “buy” rating and lifted their price target for the company from $67.00 to $79.00 in a report on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $78.25.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.